Gustavo joined AGC Biologics (previously CMC Biologics) in 2008 as President. In 2010, he was named global Chief Operations Officer and in January, 2016 he became Chief Executive Officer. Prior to joining CMC Biologics, Gustavo worked for 15 years at Bayer in the United States, Europe, and Latin America, serving in various manufacturing and general management positions.
Gustavo received his Ph.D. in Biochemistry from the University of Buenos Aires, and holds a Master of Business Administration from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.
Hiroshi joined Asahi Glass Company (AGC) Inc. in 1986 and has been engaged in variety of assignments during his more than 30 years with the company - including, purchasing, sales of architectural glass and corporate planning. During the period of 1996 to 2000, he also worked for the sales operations in Florida, California and Tennessee with a focus on special glass products imported from Japan. Hiroshi joined the Life Science Division of the Chemicals Company of AGC, Inc. in 2016 as a leader of Planning & Accounting Management. Hiroshi was appointed CFO of AGC Biologics operations in Bothell, WA in January 2018.
Hiroshi has a Bachelor Degree in Law from Tokyo University, Japan.
Patricio joined AGC Biologics (previously CMC Biologics) in August 2012 as General Manager and Managing Director of the CMC Biologics A/S based in Copenhagen. He has been working in Biologics for the last 20 years. Along his career, Patricio has held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó, and other Biotech companies in Spain, Brazil, and Argentina developing, manufacturing and controlling biotechnological products and vaccines for human health and animal health. He led a staff of more than 250 employees operating large scale manufacturing facilities. He has acted as change agent in several integration processes and developed strong leadership teams.
Patricio holds Biochemist degree from University of Buenos Aires and a Master of Business Administration from UCEMA.
Bob joined AGC Biologics (previously CMC Biologics) in 2015 and serves as Chief Business Officer, responsible for global sales and marketing. He brings more than 30 years of experience in the biopharmaceutical and contract manufacturing industries, including holding positions of Senior VP, Business Development at Gallus Biopharmaceuticals, LLC (now Patheon Biologics) and Chief Commercial Officer and Chief Executive Officer at Laureate BioPharma. His technical expertise spans research, development, protein characterization, validation, testing, and cGMP manufacture of biopharmaceutical products, from pilot to Phase III clinical and commercial scale, with a strong emphasis on monoclonal antibody products for therapeutic and diagnostic use. Bob has also held senior positions in R&D and operations at Purdue BioPharma L.P., Bard BioPharma L.P and at Cytogen Corporation.
Bob is a graduate of Rensselaer Polytechnic Institute where he earned his BS and Ph.D. degrees.
Ikuo joined Asahi Glass Co. (AGC) in 1986 as a Chemical Process Engineer in the Chemical Divisional R&D Center. He has over 30 years of experience in development of Fluorine containing polymer products. During the period of 2005 through 2009, he also worked as a corporate investor in Silicon Valley, CA, where he sought business opportunities for AGC.
Ikuo has a Master Degree in Chemistry from Yamaguchi University JP, and has held the Professional Engineer in Chemistry of Japan as a National Qualification since 2014.
SoYoung joined AGC Biologics (previously CMC Biologics) in 2015 as Vice President of Legal Affairs. She brings more than 20 years of experience as a corporate attorney and business executive with responsibility for all legal matters, including complex product licensing, research and development, commercial disputes/litigation management, board governance, corporate compliance, HR/Employment, general corporate, and transactional matters. Ms. Kwon has served as primary counsel to the board and all board committees, and has partnered with management and business leaders to achieve business initiatives.
SoYoung holds a Juris Doctorate from Willamette University College of Law and a Master of Law in Asian and Comparative Law from the University of Washington School of Law.
Paul joined AGC Biologics (previously CMC Biologics) in 2015 as Vice President for the Quality Department. He brings more than 25 years of experience in development of protein and small molecule products. Prior to CMC Biologics, he held positions of increasing responsibilities at Amgen and Eli Lilly in operations, quality, and analytical development.
Paul has a Ph.D. in Chemistry from Texas A&M University and a Bachelor of Science in Applied Chemistry from Harvey Mudd College.
Mark joined AGC Biologics in February 2018 as Senior Vice President of Integration Management and Business Excellence. Mark has over 25 years of successful experience leading large-scale business integrations and transformations of Fortune 200 client companies both as the COO of several international management consultancies, as well as with his own management and leadership consultancy corporation.
Mark holds an Executive Management Certification from Harvard Business School, a Master of Science in Organization Development from Chapman University and a Bachelor of Science in Education from Southern Illinois University.
Daisy joined AGC Biologics (previously CMC Biologics) in April 2017 as the Global Vice President of Human Resources. She brings over 18 years of professional Human Resources and Operations Management experience from various industries including Financial Services, High Tech, and Power Generation, working with organization sizes ranging from start-ups to global Fortune 100.
A native of Canada, Daisy holds an MBA from Azusa Pacific University in S. CA, and a Bachelor of Commerce degree in Human Resources Management and Entrepreneurship from McGill University in Montreal.
Jin joined AGC Biologcs in February 2018 as General Manager and Site Head of AGC Biologics' Seattle Facility and Global Headquarters. Jin brings more than 20 years of leadership experience in the biotechnology and manufacturing industry, most recently serving as Site Head of Bacterial Vaccine Manufacturing, Global Vaccines Industrial Affairs with Sanofi Group in Swiftwater, PA. Prior to Sanofi, Jin held leadership roles within multiple organizations including Bayer HealthCare, the Schering-Plough Research Institute, ImClone Systems, and Covance Biotechnology Services.
Jin holds a Master of Science and a Ph.D. in Chemical Engineering from Nagoya University.
Kasper joined AGC Biologics (previously CMC Biologics) in 2006 as a Scientist, and has held the positions of Principal Scientist (2007) and Department Manager (2008) within development. Beginning in 2010, Kasper lead the Upstream Process Development teams, and in 2011, lead process characterization and validation activities. In 2013, Kasper was appointed Vice President of Manufacturing. Prior to CMC Biologics, he spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research and teaching within fermentation technology and metabolic engineering studies.
Kasper has a Ph.D. in Biochemical Engineering from the Technical University of Denmark, and pursued post-doctoral studies at Washington University Medical School in St Louis, Missouri.
Vy joined AGC Biologics (previously CMC Biologics) in November 2014 as General Manager. He manages the startup and day-to-day site operations of CMC Biologics’ Berkeley manufacturing facility. Vy brings more than 25 years of biopharmaceutical industry expertise in the areas of clinical and commercial biologics manufacturing, strategic planning, and operations management from Bayer HealthCare.
Vy received his Bachelor of Science in Business Administration from Dominican University of California.
Dieter Kramer — General Manager and Site Head, Heidelberg Facility
Dieter joined AGC Biologics in July 2018 as the Managing Director of our facility in Heidelberg, Germany and brings more than 20 years of combined technical and leadership experience to the organization. Prior to joining AGC Biologics, he served in a similar role at Corden Biochem GmbH, a full service Contract Manufacturing Organization (CMO) also in the biotechnology space. Dieter served from 2011 to 2016 as Managing Director of Sandoz Industrial Products GmbH, an API manufacturing site of the Novartis generic division in Frankfurt am Main, Germany with large-scale fermentation and downstream capabilities. Before this assignment, Dieter held various positions in R&D, manufacturing, project management, and general management in the Sandoz/Novartis network in Austria and Germany.
Dieter earned a Master of Science in Technical Chemistry & Biotechnology from the Techniche Universitat Graz and a Master of Business Administration in General Management from the Management Center in Innsbruck.
Hiroshi Nakamura - General Manager and Site Head, Chiba Facility